The Quiet Validation
What Roche’s Double Failure Actually Tells Us About Huntington’s Disease
On July 9th, Roche killed two Huntington’s disease programs. One missed its efficacy endpoint outright. The other was stopped after three patients because animal data showed it couldn’t be dosed chronically. Roche called it coincidence — “independent, data-driven events, which have coincided by chance.”
Read together with a wave of new mechanistic biology published this same month, the coincidence is more informative than Roche’s careful corporate language lets on. It isn’t really news that two more Huntington’s drugs failed, this field has buried more candidates than it has advanced. What’s underappreciated is why they failed, and what that specifically implies about the one program still standing.